Portolan Capital Management - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
Portolan Capital Management ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2021$6,097,000
-31.7%
146,239
-30.0%
0.48%
-40.9%
Q4 2020$8,922,000
-16.4%
208,900
-48.5%
0.81%
-32.8%
Q3 2020$10,668,000
-25.4%
405,934
-23.9%
1.21%
-26.1%
Q2 2020$14,298,000
+157.0%
533,310
+72.4%
1.63%
+95.6%
Q1 2020$5,564,000309,2700.84%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Third Security, LLC 14,092,771$256,066,00016.64%
BB BIOTECH AG 8,247,860$149,864,0003.97%
MSD Partners, L.P. 2,245,000$40,792,0003.07%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 428,633$5,969,0002.84%
First Light Asset Management, LLC 885,523$16,090,0002.60%
SNYDER CAPITAL MANAGEMENT L P 2,387,350$43,378,0001.93%
Sterling Global Strategies LLC 22,000$400,0001.74%
Taylor Wealth Management Partners 221,380$4,022,0001.71%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,228,399$167,680,0001.68%
DOHENY ASSET MANAGEMENT /CA 124,393$2,260,0001.18%
View complete list of HALOZYME THERAPEUTICS INC shareholders